Showing 4191-4200 of 7513 results for "".
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair
- Senté to Introduce Intensive Bio Complete Creamhttps://practicaldermatology.com/news/sent-to-introduce-intensive-bio-complete-cream/2459927/Senté is expanding their family of skincare products with the upcoming launch of Intensive Bio Complete Cream. Slated to be available on Feb. 11, 2019, the new nighttime cream is an “advanced retinol,” explains Virginia L. Vega, Ph.D., Senté ’s Vice
- Dermatology Hall of Fame to Recognize Industry Pioneershttps://practicaldermatology.com/news/dermatology-hall-of-fame-to-recognize-industry-pioneers/2459941/The Dermatology Hall of Fame will honor its first inductees February 28, 2019, in Washington, DC. The organization, founded in 2018, was established to recognize and honor past and present luminaries within all areas of dermatology. “The field of dermatology has been furthered by tr
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- New Study Seeks to Improve Skin Cancer Prevention in Young Adults Via a New Websitehttps://practicaldermatology.com/news/new-study-seeks-to-improve-skin-cancer-prevention-in-young-adults-via-a-new-website/2457539/Researchers out of Rutgers Cancer Institute of New Jersey and colleagues from across the country are conducting a study to evaluate the reach and effectiveness of an online program targeted at skin cancer prevention in young adults. Investigators are refining an existing website to
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track